EntryPoint Capital’s Immuneering IMRX Stock Holding History

EntryPoint Capital’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-31,237	Closed	-$206K	–	829
2025 Q4	$206K	Buy	+31,237	New	+$201K	0.08%	542

Other funds holding IMRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $165M AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EntryPoint Capital's IMRX Position: Q1 2026 in Review

EntryPoint Capital sold out of Immuneering (IMRX) in Q1 2026, closing a stake of 31,237 shares — an estimated $206K sold.

EntryPoint Capital first reported a position in IMRX in Q4 2025 and held it in 1 quarter. The position peaked at $206K in Q4 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

EntryPoint Capital reported no remaining Immuneering position as of Q1 2026 after selling out during the quarter.
EntryPoint Capital sold 31,237 Immuneering shares in Q1 2026, an estimated $206K.
EntryPoint Capital first reported a position in Immuneering in Q4 2025 and held it in 1 quarter.
EntryPoint Capital's Immuneering position peaked at $206K in Q4 2025.
95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.